Hantavirus Treatment: What to Expect
There is no approved antiviral specifically for hantavirus. Survival depends on rapid recognition, immediate ICU care, and supportive management. Understanding how hantavirus is treated, and why speed of care matters, provides important context about disease prognosis.
Treating Hantavirus Pulmonary Syndrome (HPS)
The absence of an approved antiviral means treatment is entirely supportive: keeping the patient alive while the immune system clears the infection. Every hour matters — patients can deteriorate from mildly short of breath to needing a ventilator within hours.
Hospital Supportive Care
- Supplemental oxygen — via mask, high-flow nasal cannula, or non-invasive ventilation initially
- Mechanical ventilation — intubation if non-invasive methods fail to maintain oxygen levels
- ECMO (Extracorporeal Membrane Oxygenation) — used in the most severe cases; the heart-lung bypass machine oxygenates blood externally
- IV vasopressors — medications that maintain blood pressure (epinephrine, norepinephrine, dopamine)
- Careful fluid management — avoiding fluid overload which worsens pulmonary edema
- Continuous cardiac monitoring — arrhythmias and hemodynamic instability are common
Why ECMO Matters
ECMO is a form of life support that takes over the work of both the heart and lungs when they fail. It is reserved for the most severe cases — patients whose oxygen levels cannot be maintained despite maximal ventilator support. In the largest published series, among HPS patients with a predicted mortality near 100% who were placed on ECMO, roughly 60–66% survived and recovered completely (Dietl 2008; extended by Wernly and colleagues 2011). The reason this works in a disease with no antiviral is physiological: CDC's clinician brief notes that HPS "has a short duration of critical disease," that the cardiopulmonary dysfunction is driven by circulating inflammatory mediators, and that autopsies on fatal cases "did not show significant tissue damage." The organs are not destroyed; they are overwhelmed for a few days. Support the circulation through those days and the patient recovers. Because that window is narrow, if HPS is suspected in a rural hospital a transfer to an ECMO-capable facility should be arranged urgently — before the patient deteriorates further.
What the Evidence Behind Each Treatment Actually Says
Almost everything used in HPS is supportive, and the things that have been tested formally have mostly failed. Publishing the trials rather than the impressions is the honest way to present this, so here they are.
| Intervention | Best evidence | Result |
|---|---|---|
| ECMO for refractory HPS | Dietl et al., J Thorac Cardiovasc Surg 2008 — 38 patients, University of New Mexico, 1994–2006 | 60.5% survived (23 of 38) with a predicted mortality of 100%. All survivors recovered completely; mean hospital stay 20.8 days |
| ECMO, extended series | Wernly et al., Eur J Cardiothorac Surg 2011 — the same programme extended to 51 patients, 1994–2010 | 66.6% survived overall (34 of 51). Split by era: 56% in 1994–2000 (14 of 26) against 80% in 2003–2010 (20 of 25), p = 0.048 — the later group had vascular access placed pre-emptively and went on ECMO at the moment of decompensation rather than after it |
| Intravenous ribavirin for HPS | Mertz et al., Clin Infect Dis 2004 — placebo-controlled, double-blind, 36 enrolled (23 confirmed), stopped early | Survival without ECMO 70% on ribavirin against 62% on placebo; two deaths in each arm. Underpowered and terminated for futility; the authors' conclusion is that ribavirin "is probably ineffective" in the cardiopulmonary stage. CDC's clinician brief states flatly that it "was not shown to be effective" |
| Intravenous ribavirin for HFRS | Huggins et al., J Infect Dis 1991 — double-blind, placebo-controlled, 242 patients in China | A sevenfold reduction in the risk of death after adjustment for baseline risk (p = 0.01), plus fewer patients entering the oliguric phase and less haemorrhage. The one genuine positive antiviral trial in this field — and it is for the kidney disease, not the lung disease |
| High-dose methylprednisolone | Vial et al., Clin Infect Dis 2013 — double-blind randomised trial, 13 sites in Chile, 66 enrolled (60 confirmed) | 11 of 30 on steroid reached the composite endpoint against 15 of 30 on placebo, p = 0.43; no mortality difference. Safe, but "did not provide significant clinical benefit" |
| Convalescent immune plasma | Vial et al., Antivir Ther 2015 — open, non-randomised, 29 confirmed patients in Chile | 4 of 29 died (14%) against 63 of 199 (32%) among untreated Chilean cases in the same period — odds ratio 0.35 (95% CI 0.12–0.99, p = 0.049). Suggestive, but the comparison is not randomised and the confidence interval touches 1.0 |
The pattern in that table is worth naming. The two interventions with the strongest support are mechanical (ECMO) and logistical (getting on it early): the 56%-to-80% improvement in the New Mexico series came from changing when patients were cannulated, not from a new drug. Every pharmacological approach tested in HPS — antiviral, steroid — has failed to show benefit in a controlled trial.
The 80% Figure, and Why It Differs from 60–66%
CDC's clinician brief states that "initiating extracorporeal membrane oxygenation (ECMO) at the earliest sign of decompensation has an 80 percent survival rate in patients despite cardiopulmonary collapse." That is not a contradiction of the 60–66% figures above — it is the same data, narrowed. Eighty per cent is the 2003–2010 half of the New Mexico series, in which ECMO was started at the first sign of decompensation; the 56% figure is the earlier half, in which patients were intubated when they became hypoxic and cannulated only once they were haemodynamically unstable. The variable is timing. The practical consequence for a patient in a rural hospital is that the transfer decision needs to be made before it looks urgent, not after.
Correction note. An earlier version of this site overstated survival on ECMO in severe hantavirus pulmonary syndrome. The published series report 60.5% (Dietl 2008) and 66.6% (Wernly 2011) overall, with 80% in the later, early-cannulation group. The correction is recorded on our corrections page (6 August 2026).
What to Tell the ER Doctor
📋 Critical Information to Provide
- Any rodent exposure in the past 8 weeks (droppings, nesting, dead mice)
- Cleaning a cabin, barn, attic, shed, or storage space
- Camping or hiking in the Four Corners region, Southwest, or West
- Occupational exposure (agriculture, pest control, forestry)
- Travel to South America (Andes virus)
The CDC notes that hantavirus may not be in a clinician's initial differential diagnosis; providing detailed rodent exposure history is therefore essential to workup. CDC: HPS Clinician Brief
Medications Used in HPS
| Medication | Role | Evidence |
|---|---|---|
| Ribavirin (IV) | Antiviral tested for HPS | Placebo-controlled trial found no benefit and was stopped for futility (Mertz et al. 2004); CDC states it "was not shown to be effective for treatment of HPS" |
| Broad-spectrum antibiotics | Cover the illnesses HPS mimics | CDC advises giving them to suspected HPS patients "even if you're still waiting for diagnosis" — early HPS is indistinguishable from bacterial sepsis, legionella and Q fever |
| Vasopressors (norepinephrine etc.) | Maintain blood pressure | Standard of care; CDC lists monitoring and adjustment of cardiac function and careful fluid administration as the core of management |
| Inhaled nitric oxide | Pulmonary vasodilator for severe hypoxia | Used in some ECMO centres; no controlled trial in HPS |
| Corticosteroids | Immune modulation | A double-blind randomised trial of high-dose methylprednisolone in Chile found no clinical benefit (Vial et al. 2013) |
| Convalescent immune plasma | Passive antibody | Non-randomised Chilean series: 14% mortality against 32% in untreated contemporaries, OR 0.35 (95% CI 0.12–0.99). Not a licensed therapy anywhere |
Treating Hemorrhagic Fever with Renal Syndrome (HFRS)
HFRS treatment focuses on managing kidney function and fluid balance rather than respiratory support. Most patients with mild-to-moderate HFRS (Puumala virus in Europe) recover fully with supportive care.
- Fluid management — careful IV fluid balance to support kidney perfusion without overloading
- Dialysis (hemodialysis) — temporary dialysis may be required during the oliguric phase when kidneys fail to filter waste products
- Ribavirin (IV) — unlike in HPS, ribavirin works in HFRS. CDC states that "if used early in the course of the disease, the antiviral ribavirin can be given intravenously to decrease illness and death from HFRS." The underlying trial is a 242-patient double-blind, placebo-controlled study in China that found a sevenfold reduction in the risk of death after adjustment for baseline severity, along with fewer patients entering the oliguric phase and less haemorrhage (Huggins et al., J Infect Dis 1991). Its only notable side effect was a reversible anaemia. Used in China, Korea, and parts of Europe
- Electrolyte monitoring and correction — sodium, potassium, and phosphate balance require careful management
- Pain and fever control — CDC's HPS brief lists fever reducers and pain relievers as part of care. Neither CDC nor WHO publishes a hantavirus-specific instruction on avoiding NSAIDs; the general caution about non-steroidal anti-inflammatory drugs in acute kidney injury applies here as it does elsewhere, and is a decision for the treating clinician
Recovery Expectations for HFRS
CDC's position is that complete recovery from HFRS "can take several weeks to months," and that death rates vary greatly by virus — "from less than 1 percent (Puumala virus) to up to 15 percent (Hantaan virus)." Severe Hantaan infections carry a higher risk of lasting renal impairment; Puumala rarely causes permanent kidney damage. Dialysis may be needed during the oliguric phase to correct severe fluid overload.
Correction, published September 15, 2026. This section previously stated that "published clinical guidance recommends follow-up renal function monitoring for at least one year post-hospitalization for severe HFRS cases." We could not locate a CDC, WHO or ECDC guideline making that recommendation, and the sentence has been removed rather than left standing on an unverifiable attribution. Logged on our corrections page.
The scale matters for context: ECDC recorded 1,885 hantavirus infections and three deaths across the EU/EEA in 2023, 95.6% of the typed cases being Puumala (Annual Epidemiological Report, published March 2025). HFRS is far more common than HPS and far less often fatal — which is why the treatment questions differ so completely between the two.
Be Prepared: Monitoring & Emergency Essentials
Research & Future Treatments
Hantavirus drug and vaccine development has run for three decades without producing a licensed product in the Americas or Europe. What follows is what is actually registered, read from ClinicalTrials.gov on September 15, 2026 rather than from press coverage.
| Study | Phase / status | Enrolment | Sponsor |
|---|---|---|---|
| Andes virus DNA vaccine (NCT03682107) | Phase 1, completed (started February 2019) | 48 | National Institute of Allergy and Infectious Diseases |
| Hantaan/Puumala DNA vaccine (NCT04333459) | Phase 2, completed (started August 2021) | 132 | U.S. Army Medical Research and Development Command |
| Hantaan/Puumala combination DNA vaccine (NCT03718130) | Phase 1, completed | 61 | U.S. Army Medical Research and Development Command |
| Methylprednisolone for HCPS (NCT00128180) | Phase 2, completed — the negative trial described above | 66 | University of New Mexico |
| Natural History of Andes Virus Infection (NCT07703579) | Observational, active (started May 2026) | 15 | Assistance Publique – Hôpitaux de Paris |
On vaccines, the accurate statement is narrower than "there is no vaccine." Whole-virus inactivated vaccines against Hantaan or Seoul virus are licensed for human use in the Republic of Korea and in China — the reviews that describe them also say their protective efficacy is uncertain and that the immune correlates of protection are not known (Liu et al., Frontiers in Microbiology 2019; Chai et al., Vaccines 2025). No hantavirus vaccine is licensed in the United States or the European Union, and none exists for Sin Nombre or Andes virus anywhere. WHO's fact sheet takes the global view and says there is "no licenced specific antiviral treatment or vaccine for hantavirus infection."
Correction, published September 15, 2026. Several pages on this site said there was no approved hantavirus vaccine "anywhere in the world" or described the Korean and Chinese products only as having "mixed effectiveness data." Inactivated HFRS vaccines are in fact licensed for human use in the Republic of Korea and China; what is uncertain is how well they work. The claim has been narrowed on every page where it appeared to the accurate statement: no hantavirus vaccine is licensed in the United States or Europe, and none exists for the strains that cause disease in the Americas. Logged on our corrections page.
What is not known, and why progress is slow. Roughly thirty U.S. cases a year makes an efficacy trial arithmetically impossible: no realistic enrolment produces enough events to measure a survival difference. That is why the ribavirin trial was terminated for futility after five years and 36 subjects, and why the ECMO evidence comes from a single institution's case series rather than a randomised comparison. The field's plausible route forward is immunological — monoclonal antibodies and DNA vaccines that can be evaluated on antibody response rather than on survival — and that is what the registered studies above are doing.
Treatment FAQs
Is there a cure for hantavirus?
No approved antiviral exists for hantavirus pulmonary syndrome, and the drugs that have been tested formally — intravenous ribavirin and high-dose methylprednisolone — both failed in controlled trials. Treatment is supportive: maintaining oxygen and blood pressure while the immune system clears the virus. Survival depends on early ICU admission and, for the most severe cases, on ECMO. The one exception is HFRS, the kidney form, where a 242-patient placebo-controlled trial found intravenous ribavirin cut the risk of death sevenfold when given early (Huggins et al. 1991) — which is why CDC recommends it for HFRS and not for HPS.
What is the survival rate for hantavirus?
CDC's figure for HPS is that 38% of people who develop respiratory symptoms die — so roughly 62% survive. Among patients sick enough to need ECMO, with a predicted mortality of 100%, the published series report 60.5% survival (38 patients, Dietl 2008) and 66.6% (51 patients, Wernly 2011); in the later, early-cannulation half of that programme it was 80%, the figure CDC quotes. HFRS survival depends on the virus: CDC gives 5–15% mortality for Hantaan and Dobrava and under 1% for Puumala and Seoul. Across the whole EU/EEA in 2023, ECDC recorded three deaths among 1,885 reported infections.
Is there a hantavirus vaccine?
Not in the United States or Europe, and not for any of the viruses that cause disease in the Americas. Inactivated whole-virus vaccines against Hantaan or Seoul virus are licensed for human use in the Republic of Korea and in China, but published reviews state that their protective efficacy is uncertain. Several DNA vaccine candidates have completed Phase 1 and Phase 2 immunogenicity studies in the U.S. — including an Andes virus DNA vaccine (NCT03682107) and a Hantaan/Puumala combination (NCT04333459) — and none has progressed to a licensed product. The obstacle is arithmetic: with roughly thirty U.S. cases a year, no efficacy trial can accumulate enough events to measure protection.
How long does it take to recover from hantavirus?
Survivors of HPS who pass the critical phase improve quickly — CDC notes the critical illness is short and that autopsies of fatal cases show little structural tissue damage, which is the same reason recovery is usually complete. In the New Mexico ECMO series the mean hospital stay was 20.8 days (range 10–39) and every survivor "recovered completely." CDC also observes that survivors often become polyuric during convalescence and then improve rapidly. For HFRS, CDC says complete recovery "can take several weeks to months"; most patients regain full kidney function.
Sources & References
Clinical claims on this page are sourced to the following primary authorities:
- Centers for Disease Control and Prevention (CDC). Clinician Brief: Hantavirus Pulmonary Syndrome (HPS) (updated May 8, 2026; supportive-care protocol, ECMO at first decompensation, prognostic thresholds, ribavirin not effective for HPS). cdc.gov/hantavirus/hcp/clinical-overview/hps
- CDC. Clinician Brief: Hemorrhagic Fever with Renal Syndrome (reviewed May 20, 2024; ribavirin for HFRS; mortality by virus). cdc.gov/hantavirus/hcp/clinical-overview/hfrs
- CDC. About Hantavirus (reviewed May 13, 2024). cdc.gov/hantavirus/about
- World Health Organization (WHO). Hantavirus (fact sheet, 6 May 2026; no licensed antiviral or vaccine; early intensive care improves outcomes). who.int/news-room/fact-sheets/detail/hantavirus
- Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg. 2008;135(3):579–584 (38 patients; 60.5% survival). doi:10.1016/j.jtcvs.2007.11.020 · PubMed 18329474
- Wernly JA, Dietl CA, Tabe CE, et al. Extracorporeal membrane oxygenation support improves survival of patients with Hantavirus cardiopulmonary syndrome refractory to medical treatment. Eur J Cardiothorac Surg. 2011;40(6):1334–1340 (51 patients; 66.6% overall, 56% vs 80% by era, p = 0.048). doi:10.1016/j.ejcts.2011.01.089 · PubMed 21900022
- Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39(9):1307–1313. doi:10.1086/425007 · PubMed 15494907
- Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991;164(6):1119–1127 (n = 242; sevenfold reduction in mortality risk). doi:10.1093/infdis/164.6.1119 · PubMed 1683355
- Vial PA, Valdivieso F, Ferres M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013;57(7):943–951. doi:10.1093/cid/cit394 · PubMed 23784924
- Vial PA, Valdivieso F, Calvo M, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther. 2015;20(4):377–386. doi:10.3851/IMP2875 · PubMed 25316807
- Liu R, Ma H, Shu J, et al. Vaccines and Therapeutics Against Hantaviruses. Front Microbiol. 2020;10:2989 (inactivated HTNV/SEOV vaccines licensed in the Republic of Korea and China; efficacy uncertain). doi:10.3389/fmicb.2019.02989 · PubMed 32082263
- Chai S, Wang L, Du H, Jiang H. Achievement and Challenges in Orthohantavirus Vaccines. Vaccines (Basel). 2025;13(2):198. doi:10.3390/vaccines13020198 · PubMed 40006744
- ClinicalTrials.gov. Registered hantavirus studies (queried September 15, 2026): NCT03682107, NCT04333459, NCT03718130, NCT00128180, NCT07703579. clinicaltrials.gov
- European Centre for Disease Prevention and Control (ECDC). Hantavirus infection — Annual Epidemiological Report for 2023 (published March 2025). ecdc.europa.eu
Symptom Timeline
Understand the prodromal and cardiopulmonary phases so you can recognize HPS early.
Prevention Guide
Since there's no cure, prevention is everything. Complete guide here.
Outbreak History
Understand the historical and current hantavirus outbreak landscape.
How It Spreads
The exposure routes behind infection — inhaled aerosols, contact, and the Andes exception.